Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti
16/03/2021
0:00
16:48
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.
Mais episódios de "MedEdTalks - Gastroenterology"
Não percas um episódio de “MedEdTalks - Gastroenterology” e subscrevê-lo na aplicação GetPodcast.